Why is the aging brain susceptible to Alzheimers Disease? (completed)
Patterns and mechanisms of brain atrophy in healthy aging and dementia.
About the project
The prevalence of Alzheimer's Disease (AD) increases sharply from 60 years, reaching about 50% in 90 year olds. At the same time, 50% of healthy elderly report worries about their own memory function. Thus, understanding the neural foundation for cognitive decrements in both demented and healthy aging is among the most important tasks for research in neuroscience. At the heart of this question is the role of amyloid protein in neurodegeneration and memory decline in both AD and healthy aging. Current models hold that the influence of amyloid on the brain is largest in very early phases of AD, years before clinical symptoms become manifest, so it is paradoxical that the influence of amyloid on brain atrophy and memory problems in healthy elderly is little researched and with inconsistent results. Progress is hindered by methodological differences and statistically under-powered studies due to very costly data collection.
The main objective of this project is to make a giant leap forward with researchers at the forefront of aging and AD, by launching a super-size database including 500 healthy and 500 patients. Focus is on 3 major events common to normal aging and AD, the EBA triad: disturbance of Episodic memory function, reduced brain integrity and accumulation of Amyloid.The database will include calibrated measures of brain atrophy (MRI), amyloid (CSF and/ or PiB PET) and memory for asymptomatic elderly and patients with mild cognitive impairment and AD. Based on these biomarkers, cognitive scores and genetic profiles, participants will be divided into groups, spanning from very low to extremely high AD risk. This yields a unique possibility to identify commonalities and differences between amyloid and brain atrophy and memory problems across groups with different AD risks. The statistical power of this project to detect effects in healthy elderly is almost eight times higher than the largest published study to date, enabling this novel strategy.
The Research Council of Norway (BEHANDLING) 2013 - 2017.